Navigation Links
Telesso initiates post-market head-to-head peripheral IV catheter study

SYDNEY, Australia April 22, 2009 Telesso Technologies Limited, a global healthcare company, announced today that Miami Children's hospital is the first site to enroll patients in a head-to-head trial evaluating its FDA-approved guide wire-assisted peripheral IV catheter versus the industry's gold standard device for peripheral IV placement. Telesso is funding the catheter clinical trial with Vascular Pathways, Inc. 

"This post-market study represents the advancement of an important innovation in medicine designed to reduce the safety risks and costs traditionally associated with peripheral IV catheter use," said Telesso's CEO Nelson Stacks. "We are encouraged by the interest and positive feedback Telesso has received to date, and we look forward to announcing additional sites shortly with data review in Q2-Q3 of this year."

The trial will enroll approximately 400 pediatric, geriatric and oncology patients at three world-class sites who will be treated with either the novel guide-wire assisted peripheral IV catheter or the current standard of care.

About the Guide Wire-Assisted Peripheral IV Catheter

A peripheral vein is the most common site for insertion of a catheter for short-term diagnostic or therapeutic use. The catheter is placed into the peripheral vein in the arm, below the elbow and is typically passed up inside the vein to a length of 2-3 inches. Telesso's uniquely-designed guide wire-assisted peripheral IV catheter device uses a first-in-class retractable nitinol guide wire system that is believed to enable easier IV access, reduce common safety risks, significantly lessen patient pain and discomfort, and provide cost savings to facilities by lowering administrative costs associated with failed IV starts. Telesso believes this catheter device is the first clinically meaningful advancement in peripheral IV access since automatic needle retraction catheters and addresses significant unmet needs in peripheral intravenous access.

About the Telesso-VPI Agreement

Telesso Technologies Limited announced in December 2008 that it entered into a strategic agreement with Vascular Pathways, Inc. (VPI), a private company based in California, to co-develop VPI's guide wire-assisted device with the funding of the clinical trial and to potentially acquire VPI.


Contact: Jeff Riley
Cytori Therapeutics

Related medicine news :

1. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology: